Emerging Trends to Drive Deoxycholic Acid Obesity Drugs Market Growth at 14.2% CAGR Through 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Deoxycholic Acid Obesity Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size for the deoxycholic acid obesity medication has seen a swift expansion in recent times. Starting from $0.44 billion in 2024, the market is projected to escalate to $0.50 billion in 2025, marking a compound annual growth rate (CAGR) of 14.6%. The substantial growth during the precedent period is correlated with factors such as a growing inclination towards less invasive practices, an increase in aesthetic clinics and dedicated treatment centers, a budding consumer readiness to invest in cosmetic and obesity treatments, amplified clinical substantiation validating the effectiveness and safety of deoxycholic acid injections, along with an uptick in regulatory permissions and favorable policies in key markets.

How Will the Deoxycholic Acid Obesity Drugs Market Size Evolve and Grow by 2029?
In the upcoming years, the deoxycholic acid obesity drug market is primed for swift expansion, with the expectation to reach $0.85 billion in 2029, delivering a compound annual growth rate (CAGR) of 14.2%. Factors propelling this anticipated growth within the projection period involve an escalating incidence of obesity, heightened demand for non-invasive fat reduction therapies, growing consciousness regarding body aesthetics and cosmetic procedures, surging investments in R&D for fresh deoxycholic acid formulations, and the increasing accessibility of high-purity and combination therapy products. Notable trends within the forecast period encompass the progress of combination therapies, advancements in medical tech and treatment strategies, technological progression in formulation, the incorporation of digital aids and artificial intelligence for treatment strategy, and technical advancements in injection lipolysis formulations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/deoxycholic-acid-obesity-drugs-global-market-report

What Drivers Are Propelling the Growth of Deoxycholic Acid Obesity Drugs Market Forward?
The growth of the deoxycholic acid obesity drug market is expected to be fuelled by increasing obesity rates. Obesity rates indicate the proportion of a population deemed overweight or obese based on their body mass index (BMI). The escalation in obesity rates can be attributed to unhealthy eating habits, including the increased consumption of processed foods and beverages high in sugar, leading to an accumulation of excess calories as body fat. Deoxycholic acid obesity drugs aid in lowering obesity rates by destroying and removing surplus fat cells, which in turn result in specific fat reduction and enhanced body shape. As an example, data from the US-based government agency, the Centers for Disease Control and Prevention, in September 2023 showed that in 2022, 22 states recorded an adult obesity rate of 35% or higher, a slight rise from 19 states in 2021. Consequently, the growth of the deoxycholic acid obesity drug market is being driven by increasing obesity rates. Heightened demand for non-invasive body contouring options is predicted to drive the growth of the deoxycholic acid obesity drug market. These non-surgical body contouring options consist of non-invasive or minimally invasive interventions such as cryolipolysis, lasers, ultrasound or radiofrequency, aiming to decrease fat, tighten the skin, and remodel the body without surgical procedures or recovery time. The need for such non-surgical body contouring is accelerating as consumers favour safer, less invasive alternatives to traditional cosmetic surgery that offer effective fat reduction and skin tightening with minimal pain, a lower risk factor, and virtually no recuperation period. Deoxycholic acid obesity drugs contribute to non-surgical body contouring by dissolving and absorbing localized fat cells when injected into specific areas, leading to diminished stubborn fat deposits and a more desirable body silhouette without resorting to invasive surgery. To illustrate, data from the US-based professional organization, the International Society of Aesthetic Plastic Surgery, in June 2024 revealed that in 2023, botulinum toxin remained the top non-surgical procedure among all genders and age groups, with plastic surgeons conducting 8.8 million treatments globally. Additionally, hyaluronic acid procedures saw a 29% increase, reaching 5.5 million. Therefore, the growing demand for non-surgical body contouring options is fuelling the growth of the deoxycholic acid obesity drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28192&type=smp

Which Emerging Trends Are Transforming the Deoxycholic Acid Obesity Drugs Market in 2025?
Leading firms in the deoxycholic acid obesity drug industry are turning their attention towards the progression of sophisticated products, for instance, injectable deoxycholic acid obesity medications. These advancements aim to boost treatment effectiveness and better patient results. These injectable deoxycholic acid anti-obesity drugs employ deoxycholic acid, a compound capable of dissolving fat cells, which is administered through injections to specifically diminish fat in targeted areas. As an example, in March 2024, LG Chem Ltd., a corporation based in South Korea that specializes in chemicals, launched Bellacholine aimed at decreasing submental fat. This inventive, nonsurgical injection is intended to lessen moderate to severe submental fat, commonly known as double chin, by safely eliminating fat cells with the aid of deoxycholic acid. It presents benefits such as compatibility with body pH, negligible sedimentation, and enhancing skin elasticity through the process of collagen synthesis.

What Are the Key Segments in the Deoxycholic Acid Obesity Drugs Market?
The deoxycholic acid obesity drugs market covered in this report is segmented as

1) By Drug Type: ATX-101 (Deoxycholic Acid Injection Or Kybella Or Belkyra), Experimental Or Compounded Deoxycholic Acid Formulations, Combination Therapies, Oral Deoxycholic Acid Products
2) By Formulation: Injectable, Topical
3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies
4) By Application: Submental Fat Reduction, Abdominal Fat Reduction, Thighs Arms And Flanks, Lipomas And Localized Fat, Cellulite Management
5) By End-User: Aesthetic Clinics, Dermatology Clinics, Plastic Surgery Centers, Hospitals, Home Administration

Subsegments:
1) By ATX-101 (Deoxycholic Acid Injection or Kybella or Belkyra): Standard Injectable, High-Purity Formulations, Combination Injection Therapies
2) By Experimental Or Compounded Deoxycholic Acid Formulation: Clinical Trial Formulations, Compounded Customized Formulations
3) By Combination Therapies: Deoxycholic Acid + Lipolytic Agents, Deoxycholic Acid + Enzyme Therapy
4) By Oral Deoxycholic Acid Products: Capsules, Tablets, Liquid Formulations

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28192&type=smp

Who Are the Key Players Shaping the Deoxycholic Acid Obesity Drugs Market's Competitive Landscape?
Major companies operating in the deoxycholic acid obesity drugs market are AbbVie Inc., Cipla Ltd., Glenmark Life Sciences Limited, Curia Global Inc., Daewoong Pharmaceutical Co. Ltd., Actylis, ICE Pharma, Cayman Chemical Company, Nacalai Tesque Inc., Sichuan Huiyu Pharmaceutical, Conscientia Industrial, Manus Aktteva Biopharma LLP, Jeevan Chemicals & Pharmaceuticals, Anhui Chem-Bright Bioengineering Co. Ltd., GlpBio Technology LLC, Legere Pharmaceuticals, Otto Chemie Pvt. Ltd., BOC Sciences, Guangzhou Green Cross Pharmaceutical, Prodotti Chimici e Alimentari S.P.A.

What Geographic Markets Are Powering Growth in the Deoxycholic Acid Obesity Drugs Market?
North America was the largest region in the deoxycholic acid obesity drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in deoxycholic acid obesity drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28192

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.